We open pre-market on 13 Feb 2026 with Straumann Holding AG (STMN.SW) at CHF98.50, and the company’s upcoming earnings on 18 Feb 2026 are the near-term catalyst for the STMN.SW stock. The shares trade on SIX with a PE of 36.62 and volume 364,953, while the 50-day average is CHF95.65. Investors will watch revenue growth, margin trends and guidance for signs the Healthcare sector recovery is broadening.
Earnings calendar and what matters for STMN.SW stock
Straumann reports results after the market close on 18 Feb 2026, and pre-market action on 13 Feb 2026 reflects cautious positioning. Key items to watch in the STMN.SW earnings report are organic revenue, implant and ClearCorrect aligner volumes, and EPS of CHF2.69 guidance updates. Analysts will read management commentary for 2026 margin outlook and capital allocation, including the dividend of CHF0.95 per share.
Fundamentals and valuation for STMN.SW stock
Straumann’s market cap is CHF15.71B with shares outstanding 159,450,847 and trailing EPS CHF2.69. The stock’s price-to-sales is 6.09, price-to-book is 7.61, and free cash flow yield is 2.24%, highlighting premium valuation. Compared with Healthcare peers (sector avg PE 33.57), STMN.SW stock trades at a modest premium that prices in continued product leadership and digital solutions expansion.
Operational performance and growth signals for STMN.SW stock
Straumann delivered full-year revenue growth of 3.82% (FY 2024) and EPS growth of 58.44% year-over-year, evidence of improving operating leverage. Operating margin stands near 22.72%, and return on equity is 19.17%, indicating efficient capital use. Inventory days are elevated at 222.82 which may pressure near-term working capital, so watch cash conversion and operating cash flow in the earnings release.
Technical view and trading setup for STMN.SW stock
On 13 Feb 2026 the technical picture is mixed: RSI 67.64 signals near-term strength while ADX 16.81 shows no clear trend. Price sits between the 50-day average CHF95.65 and 200-day average CHF98.12, with Bollinger upper band at CHF100.59. Traders should note average volume 399,734 vs current volume 364,953, indicating below-average liquidity for a potential post-earnings move.
Meyka AI grade and model forecast for STMN.SW stock
Meyka AI rates STMN.SW with a score out of 100: 76.19 / B+ — BUY. This grade factors S&P 500 and sector comparison, financial growth, key metrics, forecasts and analyst signals. Meyka AI’s forecast model projects a yearly target CHF100.52, a monthly target CHF88.97, and a quarterly estimate CHF82.17. Relative to the current CHF98.50, the model implies a 12-month upside of 2.06% to CHF100.52 and a near-term downside of -9.68% to CHF88.97. Forecasts are model-based projections and not guarantees.
Risks, catalysts and sector context for STMN.SW stock
Risks include slower global dental demand, reimbursement pressures and elevated inventory days that could strain cash flow. Catalysts are better-than-expected implant volumes, margin expansion from digital products, and stronger ClearCorrect adoption. Within Swiss Healthcare, sector PE is 33.57; Straumann’s premium pricing reflects higher ROE and product moat but increases sensitivity to earnings misses. For more company detail see Straumann investor resources Straumann Investor. For broader market context see recent sector news on Investing.com Investing SIKA.
Final Thoughts
Key takeaways for STMN.SW stock on 13 Feb 2026: Straumann trades at CHF98.50 into earnings and carries premium multiples (PE 36.62, P/S 6.09). Short-term moves will hinge on organic revenue and margin guidance in the 18 Feb 2026 results. Meyka AI’s forecast model projects a 12-month target of CHF100.52 (implied upside 2.06%) while the monthly model near CHF88.97 flags a possible drawdown of -9.68% if demand weakens. Our balance view: the Meyka AI grade B+ (76.19) rates Straumann as a BUY based on sector positioning and historical growth, but investors should weigh premium valuation and inventory-led working capital risk. Forecasts are model projections and not guarantees. For live updates use Meyka AI’s real-time tools and the Straumann investor site before trading.
FAQs
When does Straumann report earnings and how might that affect STMN.SW stock?
Straumann reports after the market on 18 Feb 2026. The STMN.SW stock often reacts to revenue mix, implant volumes and margin guidance; better-than-expected top-line or margins could push shares above CHF100.00, while misses may widen the downside to near CHF88.97.
What valuation metrics should investors watch for STMN.SW stock?
Key metrics are PE 36.62, price-to-sales 6.09, return on equity 19.17%, and free cash flow yield 2.24%. These show premium pricing versus Healthcare peers and highlight sensitivity to earnings and cash flow changes for STMN.SW stock.
What is Meyka AI’s short-term and 12-month view on STMN.SW stock?
Meyka AI’s model projects a monthly estimate CHF88.97 and a 12-month target CHF100.52, implying -9.68% near-term risk and +2.06% upside over 12 months. These are model outputs and not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)